NCT01335191已完成1 期
Clinical Study of TUTI-16 in Asymptomatic, HIV-1 Infected Subjects Effectively Controlled by Antiretroviral Therapy and the Effects on Viral Load During a Structured Treatment Interruption
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Thymon, LLC
- 入组人数
- 27
- 试验地点
- 1
- 主要终点
- Anti-Tat Antibody Titer
研究概览
简要总结
This protocol represents the third in human study of TUTI-16, and is being conducted to gather additional safety and human immunogenicity (anti-HIV-1 Tat titers) data of subcutaneously administered TUTI-16.
详细描述
In this study, HIV-1 infected subjects on ART, with undetectable HIV-1 viral load, will be immunized with 1mg TUTI-16 or placebo in a randomized double blind fashion (prime and 3 week boost). Three weeks after the 3 week boost (week 6) ART will be stopped. HIV-1 viral load and CD4+ T-cell levels will be determined at defined intervals through 54 weeks (48 weeks Post ART discontinuation).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males and Females
- •Age ≥ 18 and ≤ 50 years at Screening
- •Body weight of 50-100 kg (inclusive) at Screening.
- •HIV-1 seropositive subjects on effective ART for > 12 months (undetectable HIV plasma viremia), viral set point before ART > 10,
- •CD4+ T-cell count ≥ 500/mm
- •No antiviral drug within 8 weeks of screening. Patients stabilized on Aciclovir and Valciclovir for more than 6 months may be enrolled.
- •Karnofsky performance status > 90% at screening.
- •In good health as determined by medical history, a baseline physical examination, vital signs, and clinical laboratory tests.
- •Subject is willing and able to sign written informed consent prior to beginning study procedures.
- •Subject is willing and able to follow instructions, comply with the protocol requirements and make all required study visits.
排除标准
- •Females planning to become pregnant during the course of the study.
- •Females with a positive pregnancy test at Screening or study enrollment.
- •Any out-of range laboratory value at screening that has not been reviewed, approved and documented as not clinically significant by the Principal Investigator.
- •Systemic infection or other vaccination within 6 weeks prior to screening. Live vaccine within 1 year of screening.
- •Autoimmune disease (e.g., psoriasis, rheumatoid arthritis, etc.) or inflammatory bowel disease confirmed by clinical history.
- •Positive at screen for HBV (by HBsAg assay) or HCV (by antibody ELISA) unless there is no active infection as judged by an elevated alanine aminotransferase (ALT) at screening.
- •Alanine aminotransferase (ALT) above the upper limit of normal at screening.
- •Hemoglobin outside of laboratory normal range at screening.
- •Absolute neutrophil counts outside of laboratory normal range at screening.
- •Platelet count outside of laboratory normal range at screening.
- •A history of significant drug allergy.
- •A general medical or psychological condition or behavior, including current substance dependence or abuse that, in the opinion of the investigator, might not permit the subject to complete the study or sign the informed consent.
- •Subjects experiencing an acute Herpetic event.
- •Any other condition or clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening that, in the opinion of the Principal Investigator would make the subject unsuitable for the study or put them at additional risk.
- •Routine or PRN consumption of immune suppressive medications that the subject is unable or unwilling to discontinue during the study.
- •Inability to understand or follow study instructions.
- •Participation in another investigational drug/vaccine study within 30 days preceding the first injection of investigational agent in this study.
结局指标
主要结局
Anti-Tat Antibody Titer
时间窗: 54 weeks
ELISA based chemiluminescent assay to determine the anti-Tat antibody response
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Clinical Study of TUTI-16 in HIV-1 Infected and Uninfected SubjectsHIV InfectionsNCT01144026Thymon, LLC15
已完成
1 期
Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected SubjectsHIV InfectionsNCT00848211Thymon, LLC24
已完成
3 期
Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)HIV-1 InfectionNCT04233216Merck Sharp & Dohme LLC35
已完成
3 期
Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive SubjectsInfection, Human Immunodeficiency VirusNCT01449929ViiV Healthcare488
已完成
1 期
A Study of TAS-116 in Patients With Solid TumorsAdvanced Solid TumorsNCT02965885Taiho Oncology, Inc.31